News and Trends 8 Jun 2018 People with Innate Resistance to HIV Could Provide a Functional HIV Cure In the process of studying HIV-infected patients who naturally don’t need therapy to control the virus, scientists have found what could become a functional cure for HIV infections. A team of researchers from France, Italy, the UK and Australia has identified a molecule that could be transferred to HIV-positive people to help […] June 8, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2018 Microbiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD UK biotech Microbiotica has entered into a multi-year collaboration with Genentech, one of the world’s first biotechs, to develop microbiome-based treatments for inflammatory bowel disease. Microbiotica, based in Cambridge, UK has entered into a collaboration with Genentech that could be worth up to €452M ($534M), a formidable amount in the microbiome space, with an undisclosed […] June 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2018 Best of European Biotech at ASCO 2018 Not able to attend the biggest cancer conference of the year? No problem. We have summarized what we think are the most interesting therapy developments presented by European biotech’s at ASCO this year. Once again, the cream of the cancer specialist crop gathered in Chicago to discuss and present the latest findings in cancer research at […] June 6, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2018 German DNA Treatment Reduces Ulcerative Colitis Symptoms Sterna Biologicals has obtained positive Phase IIa data for an ulcerative colitis treatment that uses DNA to inhibit inflammatory proteins, which could add to the diverse approaches being developed to treat inflammatory bowel disease. Sterna Biologicals, based in Marburg, Germany, has clinical data showing its ulcerative colitis treatment reduced the severity of the disease compared […] June 6, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2018 British Researchers Regenerate Tooth Enamel With Biopolymers Researchers at Queen Mary University London have found a way to grow mineralized materials that can be used to regenerate hard tissue like dental enamel. British researchers have created a material that can be used as an artificial dental enamel to prevent and treat tooth decay or tooth sensitivity. To create the enamel, the scientists […] June 5, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2018 French Biotech Raises €40M to Fight Hepatitis B and NASH Enyo Pharma has completed a Series B financing round to start Phase II trials by the end of this year testing its lead compound in two different forms of liver disease. Enyo Pharma, based in Lyon, has raised €40M from OrbiMed and other investors to start two Phase II trials testing its lead drug candidate […] June 5, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2018 British Company Gets a $100M Boost to Develop a Surgical Robotic Arm CMR Surgical has raised an impressive Series B round to develop a robotic arm to help during surgery that mirrors the movement of a human arm. CMR Surgical, based in Cambridge, UK, has raised $100M (€85M) in Series B funding to bring its surgical robot technology closer to a market launch in Europe and the US. […] June 4, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2018 FDA Puts Clinical Trial for CRISPR Therapy on Hold The FDA has put a hold on CRISPR Therapeutics’ planned Phase I/II trial testing a CRISPR gene-editing therapy in patients with sickle cell disease, which will likely delay the use of CRISPR-based therapies in humans. CRISPR Therapeutics, headquartered in Basel, Switzerland, and its partner Vertex Pharmaceuticals will have to postpone their plans to start a Phase I/II trial […] June 1, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2018 UK Biotech Wins Major Grant to Manage Chronic Pain With Antibodies Innovate UK has awarded a grant to Iontas to develop antibodies that block pain transmission by nerve cells in patients with chronic pain. Iontas, based in Cambridge, has been awarded a grant of £556K (€633K) from Innovate UK to develop its antibody platform, KnotBody, for therapeutic applications in chronic pain management. Iontas’ antibody approach could provide […] May 31, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2018 Biotech in Germany Celebrates the Closing of a €300M Fund High-Tech Gründerfonds (HTGF), a VC with a long track of biotech investments in Germany, has closed a new fund could benefit the country’s biotech scene. High-Tech Gründerfonds is a German VC that provides seed funding to high-tech startups, including several in the biotech space. The firm has now announced the final closing of a third […] May 30, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2018 This Immunotherapy Could Be The First to Treat Milk Allergy in Children DBV Technologies has shown in a Phase II trial that its skin patch could desensitize over 60% of children with strong milk allergy. DBV Technologies, one of the largest public biotechs in France, is developing a skin patch technology to treat several forms of food allergies. The company has released new, promising data on its milk […] May 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2018 Positive House Dust Mite Immunotherapy Results for UK Biotech British biotech Allergy Therapeutics reports positive early-stage results for its house dust mite immunotherapy. It’s been a good month for Allergy Therapeutics, which also reported positive Phase II results for its grass pollen allergy vaccine trial last week. It seems to be doing well, with a number of products targeting common allergies in late stage […] May 29, 2018 - 1 minutemin - By Helen Albert Share WhatsApp Twitter Linkedin Email